The in vivo toxicology market size was valued at USD 7.76 billion in 2024 and is expected to reach USD 18.62 billion by 2032, growing at a CAGR of 11.58% over 2025-2032.
The global in vivo toxicology market is undergoing radical changes, driven by increasing regulatory pressure, ethical concerns, and new emerging in vivo toxicology methods. Growing demand for safer drugs and chemicals is an important growth driver, with pharmaceutical companies and CROs focusing on improving preclinical evaluations with in vivo models. In vivo toxicology market is being powered by burgeoning research and development spending, as America's National Institutes of Health (NIH) spends more than USD 3 billion towards toxicology studies every year, and the European Union (EU) has dedicated substantial funds to alternatives and refinement in animal testing regimens in its Horizon Europe program. The U.S. in vivo toxicology market is bound by FDA and EPA regulations, which mandate animal testing for final approval, even though there is increasing pressure to include alternative methods. Nonetheless, detailed modeling of human physiology is still required to be validated in vivo for important endpoints, including immunotoxicity, reproductive toxicology, and carcinogenicity.
For instance, an updated review by the Society of Toxicology (SOT) in March 2024 reaffirmed global trends that have seen animals used for toxicology testing beginning to fall through in silico modeling and AI-assisted pathology tools, both mirroring changes in ethical and scientific views that have rippled through the in vivo toxicology market.
The increasing requirement for biologics, oncology drugs, and environmental testing will help to grow the in vivo toxicology market revenue in North America, Europe, and APAC. An increase in the size of the in vivo toxicology market continues to be seen with emerging technologies like CRISPR-genetically modified animal models, real-time in vivo biosensors, and humanized mouse models. Furthermore, a growing prevalence of chronic diseases and an uptick in preclinical pipeline drugs are putting more pressure on drug developers to perform extensive safety evaluations. Some of the leading in vivo toxicology organizations are partnering with academia and industry to fine-tune methods, minimize the number of animals used and enhance predictivity. Additionally, the European Medicines Agency (EMA) has implemented regulations for animal testing that have demanded improved protocols, which are now considered more refined and ethical under specific use stipulations. These regulations have indirectly contributed to the improvement of in vivo toxicology market analysis by enhancing study design and reproducibility.
For instance, in April 2024, Charles River Laboratories’ partnership with a biotech company for creating highly sophisticated in vivo oncology models with 3D bioprinting and AI-driven imaging to enhance efficacy across each step of tumor response analysis emphasized advancements favoring the in vivo toxicology market size.
Drivers:
Rising Drug Development Pipelines and Regulatory Toxicology Requirements
The in vivo toxicology market growth is primarily driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the growing number of drug compounds. As of 2023, more than 18,000 drugs were actively being developed globally, with many dependent on in vivo safety and efficacy testing before entering clinical trials. Regulators (FDA and EMA) still require extensive in vivo testing for safety pharmacology and toxicokinetics, for instance, for NMEs (new molecular entities) and biosimilars. Furthermore, toxicological studies are also indispensable and useful for agrochemicals, food additives, and cosmetics in terms of REACH regulations and OECD guidelines. Global spending on life sciences R&D was over USD 230 billion in 2023, and 20%-30% was invested in preclinical testing. However, growing investments in in vivo toxicology companies are the new transgenic animal models and advanced imaging technology to drive innovation.
For instance, Envigo and Labcorp have invested in automation and AI tools for data interpretation in live models. The in vivo toxicology market share is further supported by growing collaboration between industry and academia, facilitating resource sharing and knowledge transfer.
Restraints:
Ethical Challenges Surrounding Animal Use and Global Shifts Toward Non-Animal Models Are Restraining The In Vivo Toxicology Market’s Adoption Rates
The in vivo toxicology market is considerably restricted due to increasing ethical concerns towards animal testing, despite regulatory dependence. With more than 192 million animals used in experiments each year (Humane Society International), it was a practice that sparked a public uproar and demands for alternatives. Legislative changes (such as the U.S. FDA Modernization Act 2.0, passed in December 2022) that permit non-animal approaches to drug approval processes are driving subtle transformation in favor of in vivo studies.
Supply chain disruptions and lack of availability of genetically modified or some specialized animal models are also putting some pressure, particularly on the smaller in vivo toxicology companies. Moreover, increasing dependence on high-throughput in vitro and silico technologies is decreasing the necessity of live animal tests in early screening steps. Public and investor pressure has already resulted in divestments from companies that are highly dependent on animal-based science, and companies are under pressure to think differently. Some of these ethical, legislative, and technological developments are becoming barriers to the in vivo toxicology market expansion, despite the continuing need for in vivo assessments for certain toxicities assessments.
By Product
Instruments held a substantial share of the in vivo toxicology market globally in 2024, with more than 58% of the market. The prevalence is due to the increasing use of state-of-the-art imaging devices, telemetry systems, and physiological monitoring equipment for the real-time data collection of animal studies. They are also critical for the chronic and systemic toxicology studies within pharma R&D pipelines.
Consumables are also experiencing high demand as they are used repeatedly in various testing rounds. Reagents, animal diets, and surgical kits are consumed in large amounts in toxicity studies, and their repeated use, especially in multi-dose studies, warrants higher utility within CROs and in-house laboratories.
By Test Type
Acute toxicity tests dominated in 2024 with a market size of close to 34% on account of their need as a part of regulations to evaluate the immediate toxic reactions caused by drugs and chemicals. These tests are essential for screening studies and are mandated by the OECD.
The highest rate of growth for testing is in chronic test type, which is being driven by the pipeline of long-term treatment drugs. As the number of therapies for chronic diseases is increasing, there is a growing demand for long-term safety profiling for longer periods.
By Testing Facility
Based on the model, outsourced testing accounted for the larger market share of the drug discovery services market in 2024, which is primarily attributed to the cost benefits, accessibility to advanced technologies, and savings offered by outsourced testing for drug developers (including small biotech firms).
In-house testing is gaining momentum, particularly for the larger pharma companies that are investing in building standalone preclinical research units to have more control over study design, data security, and compliance.
By Toxicity Endpoint
The systemic toxicity testing segment dominated the market in 2024 and accounted for more than 29% of the market due to the compulsion that almost all drug and chemical candidates are tested to measure the multi-organ effects, which is a critical element required across any drug approval pathway.
DART research is expanding rapidly, given increasing concerns regarding drug safety in pregnancy and its effects on fertility. However, the growing demand for reproductive health products has also led to the need for specialized toxicity endpoints.
By End User
The pharma and biotech companies were the largest end users in 2024, holding about 45% of the market, supported by increasing preclinical R&D investments and demand for faster drug approvals.
Fastest-growing CROs are those benefiting from increased outsourcing by pharma and biotech companies in their efforts to reduce costs and improve scalability. Their global presence and regulatory knowledge have made them ideal for toxicity testing.
North America held 51.3% of the global share in the in vivo toxicology market in 2024 due to a robust pharmaceutical R&D industry, supportive regulations, and significant public and private investments. The U.S. in vivo toxicology market size was valued at USD 3.01 billion in 2024 and is expected to reach USD 6.63 billion by 2032, growing at a CAGR of 10.43% over 2025-2032. The US is the largest, holding more than 68% of the regional market due to the presence of sophisticated research facilities, FDA-approved test procedures, and major in vivo toxicology companies like Charles River and Labcorp. The pressure is additionally bolstered by the surge of chronic disease drug discovery and the continued growth of biologics pipelines. Canada is up and coming largely due to greater government financing in the early-stage science and blossoming biotech clusters in provinces such as Ontario and Quebec. Similarly, Mexico is emerging through an increasing number of CRO partnerships and OECD guideline adherence.
Europe is the second largest market for in vivo toxicology due to strict environmental guidelines of REACH, an established pharmaceutical industry, and public health initiatives. Germany is the regional leader, accounting for more than 26% of the European market, due to a strong toxicology R&D sector, a large pharma presence, and government-mandated safety testing schemes. A major presence is also exerted by France and the United Kingdom, mainly based on the increasing implementation of developmental and reproductive toxicity testing and intense academic-industry cooperation, respectively. The fastest-developing country in Europe is Poland, driven by increases in outsourcing and EU-funded R&D support, which is stimulating Polish CROs and GD. The regulated-led demand in the region and existing laboratory capacity make the region a major market for the long term.
Asia Pacific is expected to be the most lucrative in vivo toxicology market, with a burgeoning pharma industry, low cost of operations, and investment in research infrastructure. China is leading the way in the region with more than 40% market share primarily due to massive government investment in preclinical R&D, a well-established CRO ecosystem, and the adoption of global best practices about regulatory policy. India is the second-largest growing country, having a large number of contract research organizations and positive government reforms towards in vivo safety testing. Japan is also among the top three contributors and is strong in chronic disease research due to its aging population and increasing investments in drug discovery.
Leading vivo toxicology companies in the market include Charles River Laboratories, Envigo, The Jackson Laboratory, Taconic Biosciences, JANVIER LABS, Thermo Fisher Scientific, Danaher Corporation, Waters Corporation, Agilent Technologies, and Shimadzu Corporation.
In Feb 2025, CN Bio introduced the PhysioMimix DILI Assay Kit – Human 24, a high-throughput liver-on-a-chip system aimed at improving preclinical toxicology testing, particularly for predicting drug-induced liver injury (DILI) with greater accuracy and human relevance.
In Sep 2024, Emulate, Inc. launched the Chip-R1 Rigid Chip, a novel organ-on-chip platform with a minimally drug-absorbing design, enhancing biological modeling for ADME and toxicology studies by reducing compound loss during experiments.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 7.76 billion |
| Market Size by 2032 | USD 18.62 billion |
| CAGR | CAGR of 11.58% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Instruments, Consumables (Reagents & Kits, Animal Models)) • By Test Type (Acute, Sub-Acute, Sub-Chronic, and Chronic Test Type) • By Testing Facility (Outsourced Testing Facility, In-House Testing Facility) • By Toxicity Endpoint (Immunotoxicity, Systemic Toxicity, Carcinogenicity, Genotoxicity, Developmental & Reproductive Toxicity (DART), and Others) • By End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | GE Healthcare, Siemens Healthineers, Philips, Canon Medical Systems, Fujifilm Holdings, Samsung Medison, Hitachi Medical Systems, Toshiba Medical Systems, Providian Medical, and Mindray Medical |
Ans: The In Vivo Toxicology market is anticipated to grow at a CAGR of 11.58% from 2025 to 2032.
Ans: The market is expected to reach USD 18.62 billion by 2032, increasing from USD 7.76 billion in 2024.
Ans: The in vivo toxicology market growth is primarily driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies, and the growing number of drug compounds.
Ans: The in vivo toxicology market is considerably restricted due to increasing ethical concerns towards animal testing, despite regulatory dependence.
Ans: North America dominated the In Vivo Toxicology market.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Animal Testing Volume and Model Usage Trends (2024)
5.2 Preclinical R&D Expenditure, by Region (2024)
5.3 Regulatory Toxicology Study Volume, by Testing Type (2021–2032)
5.4 Adoption of Alternative Methods and Reduction Initiatives (2024)
5.5 Industry-Wise Utilization of In Vivo Toxicology (2024)
5.6 Regional Regulatory Frameworks and Approval Timelines (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. In Vivo Toxicology Market Segmentation, By Product
7.1 Chapter Overview
7.2 Instruments
7.2.1 Instruments Market Trends Analysis (2020-2032)
7.2.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Consumables
7.3.1 Consumables Market Trends Analysis (2020-2032)
7.3.2 Consumables Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Reagents & Kits
7.3.3.1 Reagents & Kits Market Trends Analysis (2020-2032)
7.3.3.2 Reagents & Kits Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Animal Models
7.3.4.1 Animal Models Market Trends Analysis (2020-2032)
7.3.4.2 Animal Models Market Size Estimates and Forecasts to 2032 (USD Billion)
8. In Vivo Toxicology Market Segmentation, By Test Type
8.1 Chapter Overview
8.2 Acute
8.2.1 Acute Market Trends Analysis (2020-2032)
8.2.2 Acute Market Size Estimates And Forecasts To 2032 (USD Billion)
8.3 Sub-Acute
8.3.1 Sub-Acute Market Trends Analysis (2020-2032)
8.3.2 Sub-Acute Market Size Estimates And Forecasts To 2032 (USD Billion)
8.4 Sub-Chronic
8.4.1 Sub-Chronic Market Trends Analysis (2020-2032)
8.4.2 Sub-Chronic Market Size Estimates And Forecasts To 2032 (USD Billion)
8.5 Chronic Test Type
8.5.1 Chronic Test Type Market Trends Analysis (2020-2032)
8.5.2 Chronic Test Type Market Size Estimates And Forecasts To 2032 (USD Billion)
9. In Vivo Toxicology Market Segmentation, By Testing Facility
9.1 Chapter Overview
9.2 Outsourced Testing Facility
9.2.1 Outsourced Testing Facility Market Trends Analysis (2020-2032)
9.2.2 Outsourced Testing Facility Market Size Estimates And Forecasts To 2032 (USD Billion)
9.3 In-House Testing Facility
9.3.1 In-House Testing Facility Market Trends Analysis (2020-2032)
9.3.2 In-House Testing Facility Market Size Estimates And Forecasts To 2032 (USD Billion)
10. In Vivo Toxicology Market Segmentation, By Toxicity Endpoint
10.1 Chapter Overview
10.2 Immunotoxicity
10.2.1 Immunotoxicity Market Trends Analysis (2020-2032)
10.2.2 Immunotoxicity Market Size Estimates And Forecasts To 2032 (USD Billion)
10.3 Systemic Toxicity
10.3.1 Systemic Toxicity Market Trends Analysis (2020-2032)
10.3.2 Systemic Toxicity Market Size Estimates And Forecasts To 2032 (USD Billion)
10.4 Carcinogenicity
10.4.1 Carcinogenicity Market Trends Analysis (2020-2032)
10.4.2 Carcinogenicity Market Size Estimates And Forecasts To 2032 (USD Billion)
10.5 Genotoxicity
10.5.1 Genotoxicity Market Trends Analysis (2020-2032)
10.5.2 Genotoxicity Market Size Estimates And Forecasts To 2032 (USD Billion)
10.6 Developmental & Reproductive Toxicity (DART)
10.6.1 Developmental & Reproductive Toxicity (DART) Market Trends Analysis (2020-2032)
10.6.2 Developmental & Reproductive Toxicity (DART) Market Size Estimates And Forecasts To 2032 (USD Billion)
10.7 Others
10.7.1 Others Market Trends Analysis (2020-2032)
10.7.2 Others Market Size Estimates And Forecasts To 2032 (USD Billion)
11. In Vivo Toxicology Market Segmentation, By End User
11.1 Chapter Overview
11.2 Academic and Research Institutes
11.2.1 Academic and Research Institutes Market Trends Analysis (2020-2032)
11.2.2 Academic and Research Institutes Market Size Estimates And Forecasts To 2032 (USD Billion)
11.3 Pharmaceutical & Biotechnology Companies
11.3.1 Pharmaceutical & Biotechnology Companies Market Trends Analysis (2020-2032)
11.3.2 Pharmaceutical & Biotechnology Companies Market Size Estimates And Forecasts To 2032 (USD Billion)
11.4 Contract Research Organizations
11.4.1 Contract Research Organizations Market Trends Analysis (2020-2032)
11.4.2 Contract Research Organizations Market Size Estimates And Forecasts To 2032 (USD Billion)
11.5 Others
11.5.1 Others Market Trends Analysis (2020-2032)
11.5.2 Others Market Size Estimates And Forecasts To 2032 (USD Billion)
12. Regional Analysis
12.1 Chapter Overview
12.2 North America
12.2.1 Trends Analysis
12.2.2 North America In Vivo Toxicology Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.2.3 North America In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.2.4 North America In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.2.5 North America In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.2.6 North America In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.2.7 North America In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.2.8 USA
12.2.8.1 USA In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.2.8.2 USA In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.2.8.3 USA In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.2.8.4 USA In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.2.8.5 USA In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.2.9 Canada
12.2.9.1 Canada In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.2.9.2 Canada In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.2.9.3 Canada In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.2.9.4 Canada In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.2.9.5 Canada In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.2.10 Mexico
12.2.10.1 Mexico In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.2.10.2 Mexico In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.2.10.3 Mexico In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.2.10.4 Mexico In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.2.10.5 Mexico In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3 Europe
12.3.1 Trends Analysis
12.3.2 Eastern Europe In Vivo Toxicology Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.3.3 Eastern Europe In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.4 Eastern Europe In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.5 Eastern Europe In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.6 Eastern Europe In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.7 Eastern Europe In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.8 Poland
12.3.8.1 Poland In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.8.2 Poland In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.8.3 Poland In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.8.4 Poland In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.8.5 Poland In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.9 Turkey
12.3.9.1 Turkey In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.9.2 Turkey In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.9.3 Turkey In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.9.4 Turkey In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.9.5 Turkey In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.10 Germany
12.3.10.1 Germany In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.10.2 Germany In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.10.3 Germany In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.10.4 Germany In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.10.5 Germany In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.11 France
12.3.11.1 France In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.11.2 France In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.11.3 France In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.11.4 France In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.11.5 France In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.12 UK
12.3.12.1 UK In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.12.2 UK In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.12.3 UK In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.12.4 UK In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.12.5 UK In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.13 Italy
12.3.13.1 Italy In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.13.2 Italy In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.13.3 Italy In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.13.4 Italy In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.13.5 Italy In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.14 Spain
12.3.14.1 Spain In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.14.2 Spain In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.14.3 Spain In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.14.4 Spain In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.14.5 Spain In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.3.15 Rest Of Europe
12.3.15.1 Rest Of Western Europe In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.3.15.2 Rest Of Western Europe In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.3.15.3 Rest Of Western Europe In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.3.15.4 Rest Of Western Europe In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.3.15.5 Rest Of Western Europe In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4 Asia Pacific
12.4.1 Trends Analysis
12.4.2 Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.4.3 Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.4 Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.5 Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.6 Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.7 Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4.8 China
12.4.8.1 China In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.8.2 China In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.8.3 China In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.8.4 China In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.8.5 China In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4.9 India
12.4.9.1 India In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.9.2 India In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.9.3 India In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.9.4 India In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.9.5 India In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4.10 Japan
12.4.10.1 Japan In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.10.2 Japan In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.10.3 Japan In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.10.4 Japan In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.10.5 Japan In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4.11 South Korea
12.4.11.1 South Korea In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.11.2 South Korea In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.11.3 South Korea In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.11.4 South Korea In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.11.5 South Korea In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4.12 Singapore
12.4.12.1 Singapore In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.12.2 Singapore In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.12.3 Singapore In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.12.4 Singapore In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.12.5 Singapore In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4.13 Australia
12.4.13.1 Australia In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.13.2 Australia In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.13.3 Australia In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.13.4 Australia In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.13.5 Australia In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.4.14 Rest Of Asia Pacific
12.4.14.1 Rest Of Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.4.14.2 Rest Of Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.4.14.3 Rest Of Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.4.14.4 Rest Of Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.4.14.5 Rest Of Asia Pacific In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.5 Middle East And Africa
12.5.1 Trends Analysis
12.5.2 Middle East And Africa In Vivo Toxicology Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.5.3 Middle East And Africa In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.5.4 Middle East And Africa In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.5.5 Middle East And Africa In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.5.6 Middle East And Africa In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.5.7 Middle East And Africa In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.5.8 UAE
12.5.8.1 UAE In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.5.8.2 UAE In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.5.8.3 UAE In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.5.8.4 UAE In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.5.8.5 UAE In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.5.9 Saudi Arabia
12.5.9.1 Saudi Arabia In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.5.9.2 Saudi Arabia In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.5.9.3 Saudi Arabia In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.5.9.4 Saudi Arabia In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.5.9.5 Saudi Arabia In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.5.10 Qatar
12.5.10.1 Qatar In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.5.10.2 Qatar In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.5.10.3 Qatar In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.5.10.4 Qatar In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.5.10.5 Qatar In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.5.11 South Africa
12.5.11.1 South Africa In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.5.11.2 South Africa In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.5.11.3 South Africa In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.5.11.4 South Africa In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.5.11.5 South Africa In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.5.12 Rest Of Africa
12.5.12.1 Rest Of Africa In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.5.12.2 Rest Of Africa In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.5.12.3 Rest Of Africa In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.5.12.4 Rest Of Africa In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.5.12.5 Rest Of Africa In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.6 Latin America
12.6.1 Trends Analysis
12.6.2 Latin America In Vivo Toxicology Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.6.3 Latin America In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.6.4 Latin America In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.6.5 Latin America In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.6.6 Latin America In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.6.7 Latin America In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.6.8 Brazil
12.6.8.1 Brazil In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.6.8.2 Brazil In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.6.8.3 Brazil In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.6.8.4 Brazil In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.6.8.5 Brazil In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.6.9 Argentina
12.6.9.1 Argentina In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.6.9.2 Argentina In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.6.9.3 Argentina In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.6.9.4 Argentina In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.6.9.5 Argentina In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
12.6.10 Rest Of Latin America
12.6.10.1 Rest Of Latin America In Vivo Toxicology Market Estimates And Forecasts, By Product (2020-2032) (USD Billion)
12.6.10.2 Rest Of Latin America In Vivo Toxicology Market Estimates And Forecasts, By Test Toxicity Endpoint (2020-2032) (USD Billion)
12.6.10.3 Rest Of Latin America In Vivo Toxicology Market Estimates And Forecasts, By Testing Facility (2020-2032) (USD Billion)
12.6.10.4 Rest Of Latin America In Vivo Toxicology Market Estimates And Forecasts, By Toxicity Endpoint (2020-2032) (USD Billion)
12.6.10.5 Rest Of Latin America In Vivo Toxicology Market Estimates And Forecasts, By End User (2020-2032) (USD Billion)
13. Company Profiles
13.1 Charles River Laboratories
13.1.1 Company Overview
13.1.2 Financial
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.2 Envigo
13.2.1 Company Overview
13.2.2 Financial
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.3 The Jackson Laboratory
13.3.1 Company Overview
13.3.2 Financial
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.4 Taconic Biosciences
13.4.1 Company Overview
13.4.2 Financial
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.5 JANVIER LABS
13.5.1 Company Overview
13.5.2 Financial
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.6 Thermo Fisher Scientific
13.6.1 Company Overview
13.6.2 Financial
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.7 Danaher Corporation
13.7.1 Company Overview
13.7.2 Financial
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.8 Waters Corporation
13.8.1 Company Overview
13.8.2 Financial
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.9 Agilent Technologies
13.9.1 Company Overview
13.9.2 Financial
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.10 Shimadzu Corporation
13.10.1 Company Overview
13.10.2 Financial
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
14. Use Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Instruments
Consumables
Reagents & Kits
Animal Models
By Test Type
Acute
Sub-Acute
Sub-Chronic
Chronic Test Type
By Testing Facility
Outsourced Testing Facility
In-House Testing Facility
By Toxicity Endpoint
Immunotoxicity
Systemic Toxicity
Carcinogenicity
Genotoxicity
Developmental & Reproductive Toxicity (DART)
Others
By End User
Academic and Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players